



Contents lists available at ScienceDirect

Biochimica et Biophysica Acta

journal homepage: www.elsevier.com/locate/bbamcr

Transglutaminase 2 interacts with syndecan-4 and CD44 at the surface of human macrophages to promote removal of apoptotic cells



Vinod Nadella^{a,b}, Zhuo Wang^{a,b}, Timothy S. Johnson^c, Martin Griffin^{a,b,*}, Andrew Devitt^{a,b,**}

^a School of Life & Health Sciences, Aston University, Birmingham B4 7ET, UK

^b Aston Research Centre for Healthy Ageing, Aston University, Birmingham B4 7ET, UK

^c Academic Nephrology Unit (Sheffield Kidney Inst.), School of Medicine, University of Sheffield, Beech Hill Rd., Sheffield S10 2RZ, UK

ARTICLE INFO

Article history:

Received 2 May 2014

Received in revised form 7 September 2014

Accepted 19 September 2014

Available online 29 October 2014

Keywords:

Macrophages

Transglutaminase 2

Syndecan 4

CD44

Apoptotic cell clearance

Heparan sulphate proteoglycan

ABSTRACT

Tissue transglutaminase (TG2) is a multifunctional protein cross-linking enzyme that has been implicated in apoptotic cell clearance but is also important in many other cell functions including cell adhesion, migration and monocyte to macrophage differentiation. Cell surface-associated TG2 regulates cell adhesion and migration, via its association with receptors such as syndecan-4 and $\beta 1$ and $\beta 3$ integrins. Whilst defective apoptotic cell clearance has been described in TG2-deficient mice, the precise role of TG2 in apoptotic cell clearance remains ill-defined. Our work addresses the role of macrophage extracellular TG2 in apoptotic cell corpse clearance. Here we reveal TG2 expression and activity (cytosolic and cell surface) in human macrophages and demonstrate that inhibitors of protein crosslinking activity reduce macrophage clearance of dying cells. We show also that cell-impermeable TG2 inhibitors significantly inhibit the ability of macrophages to migrate and clear apoptotic cells through reduced macrophage recruitment to, and binding of, apoptotic cells. Association studies reveal TG2–syndecan-4 interaction through heparan sulphate side chains, and knockdown of syndecan-4 reduces cell surface TG2 activity and apoptotic cell clearance. Furthermore, inhibition of TG2 activity reduces crosslinking of CD44, reported to augment AC clearance. Thus our data define a role for TG2 activity at the surface of human macrophages in multiple stages of AC clearance and we propose that TG2, in association with heparan sulphates, may exert its effect on AC clearance via a mechanism involving the crosslinking of CD44.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

Transglutaminases are a family of enzymes that catalyse covalent bond formation between lysine and glutamine-residues in target proteins leading to their post-translational modification [1]. TG2 is the most widely expressed family member [2] and is found both in the cytoplasm and extracellularly at the cell surface [3]. When externalized, TG2 is found associated with integrins [4] and heparan sulphates (HS) [5–8]. Following translocation to the cell surface, it is deposited into the extracellular matrix [3]. Whilst protein cross-linking is the most studied function of TG2, it also participates in other biological processes unrelated to its transamidase activity [9] – e.g. cell adhesion through

cell surface association with integrins [4] and syndecans [5,6,8,10,11]. However recent work has shown that the extracellular crosslinking activity of TG2 is involved in S100A4-related cell migration involving a syndecan-4 and $\beta 1$ integrin co-signalling pathway [12].

Unwanted cells within the body are removed by apoptosis, a process which culminates in apoptotic cell (AC) removal by professional phagocytes (macrophages) and accompanying anti-inflammatory responses to prevent inflammatory and autoimmune conditions [13]. Removal of AC is an integrated, multistep process that in vivo involves recruitment of macrophages. This is followed by recognition and binding of cell corpses prior to engulfment (phagocytosis) through the use of a range of receptors and soluble bridging molecules to bind dying cell ligands [14–17]. Tissue transglutaminase (TG2) has been shown to play an important role in this process.

Important previous work utilised TG2^{-/-} mice to reveal defective clearance of AC and reduced TGF- $\beta 1$ with strong association with inflammation and autoimmunity [18]. A further detailed study defined a role for cell surface TG2 in engulfment of AC through phagocytic portal stabilisation [19]. In this context TG2 was shown to function through the interaction with $\beta 3$ integrin and the AC opsonin MFG-E8. Despite this significant previous work, the molecular associations and function of TG2 at the surface of human macrophages have not been fully defined.

Abbreviations: AC, apoptotic cell; M ϕ , macrophage; HMDM ϕ , human monocyte-derived macrophage; TG2, transglutaminase-2; SDC4, syndecan-4; PRR, pattern-recognition receptor; MDC, monodansylcadaverine; HSPG, heparan sulphate proteoglycan; HS, heparan sulphate; PMA, phorbol 13-myristate 12-acetate; VD3, dihydroxyvitamin D3; gpITG, guinea pig liver transglutaminase; HRP, horseradish peroxidase; ECM, extracellular matrix; BTC, biotin-cadaverine

* Correspondence to: M. Griffin, School of Life & Health Sciences, Aston University, Birmingham, UK. Tel.: +44 121 204 3942; fax: +44 121 204 5142.

** Correspondence to: A. Devitt, School of Life & Health Sciences, Aston University, Birmingham, UK. Tel.: +44 121 204 4165; fax: +44 121 204 5142.

E-mail addresses: m.griffin@aston.ac.uk (M. Griffin), a.devitt1@aston.ac.uk (A. Devitt).

The aim of this study was to characterise TG2 in the context of human macrophages. Using a panel of TG2 inhibitors, including both known cell-permeable and cell impermeable inhibitors, TG2 targeted siRNA and an inhibitory antibody; we reveal a role of TG2 in the different phases of AC clearance (phagocyte recruitment and AC tethering) and also define the cellular site of action of TG2. Furthermore we demonstrate for the first time the importance of syndecan-4 in the macrophage cell surface localisation of TG2 which is required for efficient clearance of apoptotic cells. Recent studies have highlighted a role for cross-linked macrophage CD44 in augmenting AC clearance [20]. Here we further address the involvement of TG2 in interacting with CD44 to promote AC clearance.

2. Materials and methods

2.1. General reagents

The general reagents were purchased from Sigma-Aldrich (Poole, UK), unless stated otherwise. Purified guinea pig liver transglutaminase (gpITG), biotin-cadaverine (BTC) and the cell permeable TG2 inhibitor Z-DON (*Z-DON-Val-Pro-Leu-OMe*) were purchased from Zedira (Darmstadt, Germany). The monoclonal TG2 activity-blocking antibody D11D12 (GB patent filing 1209096.5) was a kind gift from Dr. Tim Johnson (Sheffield University, UK). The TG2 inhibitor 1,3-dimethyl-2-imidazolium derivative R283 [21] and the peptidic TG2 inhibitors R294 and R281 were synthesized at Aston University [22,23]. Inhibitor R281 is a membrane-impermeable, irreversible TG2 inhibitor [22,23]. R294 shows greater specificity for TG2 over other TG family members [24] and is more water-soluble than R281 and is thus considered to be similarly membrane impermeable [22]. Cell permeability of R283 has not been formally demonstrated and Z-DON is reported to be cell permeable (Zedira). R281, R283 and R294 were used at 500 μ M unless otherwise stated. Monodansylcadaverine (MDC) was used at 100 μ M.

The commercial antibodies used in this study are listed in Supplementary Table 1. All blots were undertaken using the indicated mouse monoclonal antibodies. Immunofluorescence studies utilised either mouse monoclonal or rabbit polyclonal antibodies as indicated.

2.2. Cell lines, cell isolation and culture

THP-1 (human myelomonocytic cell lines; ATCC) and Mutu I BL [25] were cultured in an RPMI-1640 medium (PAA, Yeovil, UK) containing 2 mM L-glutamine supplemented with 10% FCS (PAA, Yeovil, UK) and 100 IU/ml penicillin and 100 μ g/ml streptomycin. Cells were cultured at 37 °C in a humidified environment at 5% CO₂.

Primary blood mononuclear cells were isolated from citrated blood of healthy volunteers, following informed consent, by dextran sedimentation and Percoll fractionation [26]. Monocytes were allowed to adhere to tissue culture wells (24 well plates) for 1 h prior to removal of other cells by washing with serum-free RPMI. Isolated monocytes were cultured for 7–8 days in a macrophage-SFM medium (Invitrogen Corp., Paisley, UK) at 37 °C in a 5% CO₂ incubator [27].

2.3. THP-1 differentiation to macrophage-like cells

Differentiation of THP-1 into macrophage-like cells was induced by treating THP-1 cells with 250 nM phorbol ester (PMA; Sigma, UK), 100 nM dihydroxyvitamin D3 (VD3; Enzo Life Sciences, UK) or both (DS: double-stimulated) for 48–72 h at 37 °C in a 5% CO₂ incubator in growth medium. Differentiation was confirmed by light microscopy [28].

2.4. Apoptosis induction and quantification

Mutu I (Burkitt's lymphoma cells) were exposed to 100 mJ/cm² UV-B irradiation, using a Chromata-vue C71 light box and UVX radiometer

(UV-P Inc., Upland, CA, USA) and incubated for 16 h to allow apoptosis to proceed [29]. For analysis of apoptotic nuclear morphology, cells were fixed in 1% (w/v) formaldehyde in PBS, stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma, 250 ng/ml in PBS) for 5 min and observed using inverted epifluorescence microscopy. For quantitative analyses, cells stained for 5 min with acridine orange (Sigma, 10 μ g/ml in PBS) were enumerated as a percentage of apoptotic cells per total number of cells counted per sample using a Zeiss Axiovert 200M fluorescence microscope (Carl Zeiss Ltd, Welwyn Garden City, UK) and a Hamamatsu Orca camera driven by Volocity (Perkin-Elmer, UK).

2.5. Annexin V labelling and flow cytometry

UV irradiated Mutu BL were stained with annexin V-FITC (eBiosciences Ltd., UK). Briefly, cells were washed once by centrifugation (200 \times g, 5 min) and resuspended in a binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 2.5 mM CaCl₂) containing annexin V-FITC (1 μ l per 2 \times 10⁵ cells) for 15 min on ice. Following washing once with binding buffer, cells were resuspended in 1 ml of the binding buffer containing propidium iodide at a final concentration of 20 μ g/ml. Samples were analysed immediately on a Quanta SC flow cytometer (Beckman Coulter, High Wycombe, UK). A minimum of 5000 events was collected.

2.6. Assays of phagocyte interaction with apoptotic cells

Interaction (defined as tethering plus phagocytosis) of apoptotic Mutu by phagocytes (THP-1 derived macrophages, HMDM \emptyset) was carried out in 24-well plates [30]. Briefly, phagocytes and AC at a ratio of 1:100 were co-cultured for 1 h at 37 °C (for interaction) or 20 °C (for tethering alone) in RPMI containing 0.2% (w/v) bovine serum albumin (Sigma). In assays using inhibitors (e.g. TG2 inhibitors, P1 peptide), macrophages were treated with appropriate concentrations of inhibitors in serum-free RPMI for 1 h before and throughout the co-culturing with apoptotic cells (2 h total). Unbound apoptotic cells were removed by extensive washing with PBS and cells fixed with 1% (w/v) formaldehyde in PBS. Cells were stained with DiffQuick II (Medion Diagnostics GmbH, Switzerland) for 2 min, the stain replaced with PBS and cells scored by light microscopy for the percentage of macrophages interacting with apoptotic cells. At least 200 macrophages were scored in each of the triplicate wells per experiment and at least three independent replicates were undertaken. For the assay of only tethering of AC to macrophages (i.e. excluding phagocytosis), co-culturing was carried at room temperature (20 °C), a temperature non-permissive for phagocytosis [29].

2.7. Western blotting

Cells were washed with ice-cold PBS, pH 7.4 and lysed with a cell lysis buffer (50 mM Tris-HCl, pH 7.4, containing 1% (v/v) Nonidet, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 1 mM benzamide, 1 mM NaF, 1 mM Na₃VO₄, 0.1 mM phenylmethylsulphonyl fluoride (PMSF) and a 1% (v/v) protein inhibitor cocktail (Sigma)). Protein quantity in samples was estimated by the DCTM-protein assay (detergent-compatible, Biorad). Following protein quantification, lysates containing 50 μ g of protein were dissolved with an equal volume of 2 \times Laemmli buffer (Sigma), heated to 95 °C for 5 min and resolved by standard SDS-polyacrylamide gel electrophoresis. Following electro-blotting to nitrocellulose (0.45 μ m; GE Healthcare, UK), membranes were blocked with 5% w/v non-fat milk in TBS-Tween (50 mM Tris, 150 mM NaCl, 0.05% v/v Tween 20; pH 7.4) and probed using specific primary mouse monoclonal antibodies (1:1000 dilution; Supplementary Table 1). Anti-mouse secondary antibody (1:2000 dilution; GE Healthcare) conjugated with horseradish peroxidase (HRP) was used to detect primary antibodies. Detection was carried out by using ECL chemiluminescence (GE Healthcare, UK). Equal loading was verified by using mouse

anti- α -tubulin/ β -actin antibodies (1:2000 dilution) and normalisation undertaken using densitometry where appropriate.

2.8. Heparinase-treatment of cell surface proteins

Heparan sulphate side chains were removed from the surface of cells by treatment of cells with heparinase II or, as a control, chondroitinase. Briefly, THP-1-derived macrophages were treated with heparinase II (5 units/ml) or chondroitinase (5 units/ml) in serum-free RPMI (1 h, 37 °C). Following incubation cells were washed three times with a complete culture medium (RPMI supplemented with serum) prior to use in further experiments (e.g. assays of macrophage function for AC interaction).

2.9. Isolation of cell surface proteins using biotinylation

Biotinylation of cell surface proteins was carried out, to permit purification and assessment of cell surface proteins in isolation from other cell components, as described previously [6]. Briefly, cells were rinsed with ice-cold PBS (pH 8.0) and were labelled with 0.8 μ M Sulfo-NHS-LC-biotin (Pierce) dissolved in PBS (pH 8.0) at 4 °C for 20 min. Following washing with 50 mM Tris-HCl (pH 8.0) cells were lysed in 1% (w/v) SDS in PBS with benzonase (1:1000 of 250U/ μ l) for 30 min on ice. Cell lysates containing 600 μ g of protein, following centrifugation at 13,000 \times g for 20 min to remove non-broken cells, were added to 50 μ l Neutr-Avidin-Agarose resin beads (Pierce) which were initially washed with PBS supplemented with 1% (w/v) BSA and incubated at 4 °C overnight on a rotating platform. After washing with PBS, resin bead bound biotin-labelled cell surface proteins were extracted by boiling with the 2 \times Laemmli buffer and analysed by western blotting. A non-biotinylated cell sample was also run to ensure that the pull-down was specific only for cell surface biotinylated TG2 (Supplementary Fig. 1A).

2.10. Co-immunoprecipitation to study protein association

Co-immunoprecipitation to detect interaction between proteins was carried out as described previously [11]. Briefly, cell lysates (equivalent of 150 μ g of protein) were pre-cleared by the addition of 50 μ l of washed protein-G-Sepharose beads (GE Healthcare) for 1 h prior to bead removal by centrifugation (13,000 \times g, 10 min). Approximately 0.5 μ g of appropriate mouse monoclonal antibody was added to pre-cleared cell lysates and incubated for 90 min at 4 °C on a rocking platform to form immunocomplexes with the respective protein of interest. Immunocomplexes were pulled down by incubating with protein-G-Sepharose beads (50 μ l), the beads washed in PBS three times prior to harvest by centrifugation. Immunocomplexes were subsequently collected via boiling in 30 μ l of 2 \times Laemmli buffer. Immunocomplexes with an isotype control antibody (mouse IgG1/ κ : MoPC21) were also pulled down as a known negative control to exclude the possibility that the protein of interest is binding non-specifically to beads or antibody. Immunoprecipitated proteins were separated using SDS-PAGE and detected via western blotting by using specific antibodies.

2.11. Assessment of cell surface TG2 activity via biotin cadaverine incorporation

Measurement of TG2 activity via biotin cadaverine incorporation into fibronectin was carried as described previously [5,11] with minor modifications. Briefly, a 96-well plate was coated with 5 μ g/ml of fibronectin in wash buffer (50 mM Tris-HCl, pH 7.4) overnight at 4 °C. After rinsing wells with 50 mM Tris-HCl (pH 7.4) and blocking with 3% (w/v) BSA in 50 mM Tris-HCl, pH 7.4 (30 min, 37 °C), cells were seeded into the wells at 2×10^4 per well in serum-free RPMI medium containing 0.132 mM biotin-cadaverine. Wells with 100 ng of gp1TG with 10 mM Ca^{2+} or 10 mM EDTA are used as positive and negative controls, respectively. Following incubation for 2 h at 37 °C (in the presence of

inhibitors as appropriate to the individual experiment), the reaction was terminated by the addition of 2 mM EDTA in PBS, pH 7.4 and the cells were removed by 0.1% (w/v) deoxycholate in 2 mM EDTA in PBS, pH 7.4. After rinsing wells with wash buffer and blocking with 3% (w/v) BSA in 50 mM Tris-HCl, pH 7.4 for 30 min at 37 °C, biotin-cadaverine incorporated into fibronectin was detected by incubating at 37 °C for 1 h with blocking buffer conjugated with HRP-conjugated Extr-avidin (1:1000; Sigma-Aldrich, UK). HRP was detected using OPD (Sigma) and colour development was terminated by the addition of 50 μ l of 2.5 M H_2SO_4 . The absorbance was measured at 492 nm.

Similarly, biotin cadaverine incorporation into TG2-CD44 cross-linking was also carried out, where 1×10^5 THP-1/DS M \emptyset was pre-incubated with 8 μ M biotin-cadaverine in the presence or absence of non cell-permeable TG2 inhibitor R281 in a serum-free RPMI medium at 37 °C for 2 h. Where R281 was used, M \emptyset was pre-treated with an inhibitor for 1 h prior to the addition of BTC. Following BTC incorporation, cell lysates equivalent to 150 μ g protein were subject to pull-down of biotin-containing molecules by Neutr-Avidin-Agarose resin beads. The pull-downs were probed by western blotting for CD44 to reveal TG2-mediated BTC incorporation into CD44.

2.12. Chemotaxis and migration studies

M \emptyset chemotaxis towards AC was studied using a Dunn chemotaxis chamber (Hawksley, Sussex) in conjugation with time-lapse microscopy [31]. This horizontal migration chamber establishes a true gradient of attractant rather than the 'step gradient' associated with use of vertical transwell-based systems. THP-1/DS cells, treated as appropriate with cell-impermeable TG2 inhibitor R281 (1 h in serum-free RPMI medium), were detached into 5 mM EDTA in PBS at 37 °C and reseeded to plastic cover slips. Following incubation at 37 °C for 20 min in RPMI, the coverslip was inverted on a chemotaxis chamber and sealed in position using wax with chemoattractants in the outer well. Cell migration was recorded using time-lapse microscopy (Zeiss Axiovert 200M controlled by Improvion Volocity software). Quantitative assessment of collected sequential images to allow mapping of individual cells was carried out using Image J and the Ibidi Chemotaxis and Migration tool (version 2.0, Ibidi), which provides measures of distance migrated (Euclidian) and directness.

2.13. Immunofluorescence staining

To detect cell surface proteins by indirect immunofluorescence, cells at 5×10^4 per well on multi-well glass slides (Hendley, Essex, UK) were blocked with 3% (w/v) BSA in PBS (pH 7.4) for 30 min on ice. Following washes with PBS, cells were incubated with primary mouse monoclonal antibodies (1:100 dilution) or rabbit polyclonal antibodies (1:100 dilution), in serum-free RPMI for 2 h on ice. Cell washing with PBS, pH 7.4 was followed by incubation with specific secondary antibody reagents (anti-mouse or anti-rabbit as appropriate) conjugated with either FITC or PE (1:100 dilution) for 2 h on ice. Stained cells were washed twice with PBS, fixed with 1% w/v formaldehyde in PBS and mounted with Vectashield containing DAPI (Vector Laboratories). Cells were examined using confocal microscopy (Leica Microsystems).

2.14. siRNA silencing of individual cellular components

Four different siRNAs targeting human syndecan-4 and another four different siRNAs targeting TG2 were used to inhibit/knockdown the expression of both the proteins, while the non-silencing control siRNA was used as the negative control. All siRNA were supplied at 10 μ M (Qiagen). Transfection was carried out according to manufacturer's protocol with slight modifications. Briefly, 5×10^5 THP-1 cells were seeded (1.5 ml) to 6-well plates and were stimulated with PMA and VD3 to differentiate to macrophage-like cells. Following 24 h of differentiation, cells were transfected by the dropwise addition of 100 μ l of transfection mix

(1 μ l siRNA, 9 μ l HiPerfect transfection reagent (Qiagen), 90 μ l serum-free RPMI). Following 48 h of incubation with the siRNA, whole cell lysates were used to analyse the level of protein expression by western blotting. Additionally cells at this same time point were used for additional functional studies as appropriate.

2.15. Statistical analysis

Data are expressed as the mean \pm S.E. for at least three independent replicate experiments ($n \geq 3$). Statistical tests were undertaken using InStat (GraphPad, La Jolla, CA, USA). Statistical analysis of results was undertaken using one-way analysis of variance (ANOVA) using a post-test depending on the requirement.

3. Results

3.1. TG2 inhibitors reduce M ϕ –AC interaction through actions on macrophages

Initial studies sought to address whether THP-1 cells, stimulated to differentiate to M ϕ , express TG2 as this cell model provides a valuable tool for undertaking many experiments in a controllable system. Thus we undertook western blot analysis for TG2 on cell lysates of THP-1 cells (stimulated with dihydroxyvitamin D₃, PMA or PMA/VD₃) and analysed for the presence of M ϕ cell surface TG2 following cell surface biotinylation. We show that stimulated THP-1 cells (PMA or PMA/VD₃) express TG2 strongly and this expression includes cell surface expression (Fig. 1A and Supplementary Fig. 1A). Cell surface expression was also clearly revealed with immunofluorescence microscopy (Fig. 1A) in PMA and PMA/VD₃ cells but not in THP-1 cells or VD₃ cells. The lack of detectable cell surface TG2 in THP-1 cells or those stimulated solely with VD₃ is consistent with the lack of TG2 expression noted in whole cell lysates.

To confirm a role of TG2 in human M ϕ clearance of AC, THP-1 M ϕ (THP-1/PMA, THP-1/VD₃ and THP-1/DS) were treated initially with TG2 inhibitors R283 & Z-DON (the latter is claimed to be cell permeable by the manufacturer Zedira) or R281 and R294 (R281 is cell-impermeable [22,23] and R294 more water soluble and likely therefore to be similarly cell-impermeable [22]), irreversible TG2 site-directed inhibitors [22]. The inhibitors were used at 500 μ M except Z-DON which was used at 100 μ M. Following a 1 h inhibitor treatment, macrophages were assessed for their ability to interact with apoptotic B cells, where interaction is defined as the sum of both tethering (binding) and phagocytosis (engulfment) of AC. All four TG2 inhibitors including the cell-impermeable inhibitors 281 and 294 reduced significantly M ϕ –AC interaction in those M ϕ that expressed TG2 (THP-1/PMA, THP-1/DS; Supplementary Fig. 2A), suggesting that TG2 is mediating its actions at the cell surface. Further studies revealed the inhibitor effects to be dose dependent (Fig. 2B and Supplementary Fig. 2B) with no cellular toxicity (Supplementary Fig. 3). AC clearance by phagocytes is a multistage process and to assess the role of TG2 in the tethering of AC to M ϕ , TG2 inhibitors were added to M ϕ –AC co-cultures at 20 $^{\circ}$ C, a temperature non-permissive of phagocytosis [29]. Inhibition of cell tethering was shown by all the TG2 inhibitors tested (Fig. 1C). Similarly, the inhibitors reduced AC interaction with primary human monocyte-derived macrophages (Fig. 1D).

In order to identify the cellular target of TG2 inhibition M ϕ or AC were individually treated with TG2 inhibitors prior to co-culture. Treatment of M ϕ led to the most profound reduction in M ϕ –AC interaction (Fig. 1E), suggesting that the principal TG2 inhibition effect is on the M ϕ not the AC, and that M ϕ TG2 is required for M ϕ –AC interaction. This is further supported by TG2 expression studies (Supplementary Fig. 3) since in leucocyte cells used as apoptotic targets, TG2 was not detectable by western blot. These data support a prominent role of TG2 in M ϕ –AC interaction in those highly differentiated human M ϕ

cells (HMDM ϕ , THP-1/PMA, THP-1/DS) but not in the monocyte-like models (THP-1 and THP-1/VD₃).

3.2. TG2 inhibitors reduce M ϕ migration towards AC-derived microparticles

Macrophage migration to dying cells is an important event in vivo for phagocytic removal of AC and M ϕ has been shown to migrate towards AC along a gradient of AC-derived microparticles [29]. To determine the role of TG2 on M ϕ migration to AC, THP-1 cells double-stimulated with PMA/VD₃ (DS) were assessed for their migration towards AC microparticles in the presence or absence of the TG2 cell-impermeable inhibitor R281. Inhibition of TG2 resulted in a dramatic loss of M ϕ migration towards AC (Fig. 2A), with a parallel effect on M ϕ directionality (Fig. 2A). Direct (Euclidean) distance migrated between start and end points and velocity of migration had reduced significantly with TG2 inhibitor treatment (Fig. 2B).

3.3. TG2 knockdown in M ϕ showed limited ability to interact with AC

To further confirm a role of TG2 in M ϕ –AC interaction, THP-1 cells were transfected with four different siRNA targeting human TG2, while the global non-silencing (NS) siRNA was used as the control. After stimulating THP-1 with PMA and VD₃ for 24 h, cells were transfected with siRNA for a further 48 h before whole cell lysates were analysed by western blotting for TG2 expression (Fig. 3A). TG2 siRNA1 caused a reduction (approximately 70%) in TG2 expression, in comparison to NS siRNA, and this TG2 knockdown reduced interaction between siRNA1-treated macrophages and AC by around 50% when compared to the inactive control siRNA transfected cells (Fig. 3B). Importantly, the reduced M ϕ –AC interaction noted with either the cell-impermeable TG2 inhibitor (R281) or siRNA knockdown of TG2, acting either independently or in combination, could be partially rescued by the addition of exogenous active TG2 (Fig. 3C) indicating the specificity of action of the TG2 effects shown here and confirming that active TG2 at the M ϕ cell surface is important for apoptotic cell clearance.

3.4. Cell surface TG2 protein cross-linking activity mediates M ϕ –AC interaction

Site-directed TG2 irreversible inhibitors can block both the transamidating activity and alter TG2 conformation by holding it in its open conformation after reaction [32]. Such changes to TG2 conformation could affect binding of TG2 to its high affinity ligands such as heparan sulphates [6]. To address the involvement of TG2 activity and/or conformation in M ϕ –AC interactions, the use of the competitive primary amine substrate monodansylcadaverine (MDC) at a concentration of 100 μ M, which also blocks protein cross-linking was used. MDC reduced M ϕ –AC interaction to the same degree as the irreversible cell-impermeable inhibitor R281; suggesting that alterations to TG2 activity, not conformation were responsible for altered AC clearance (Fig. 4A).

Given that our results suggest that the activity of cell surface TG2 is important in AC clearance, we next demonstrated the presence of in situ cell surface TG2 activity in live cells (Fig. 4B) using established techniques [5,11]. This activity was inhibited using our panel of TG-2 inhibitors. Add-back of purified exogenous active TG2 to the inhibitor treated M ϕ resulted in a partial rescue of TG2 activity (Fig. 4B). Primary human M ϕ showed a similar pattern of cell surface TG2 activity (Supplementary Fig. 5). Additionally, TG2 knockdown by siRNA resulted in the loss of cell surface TG2 activity (Fig. 4C) consistent with reduced TG2 expression (Fig. 3A). Furthermore, a specifically targeted TG2 activity-blocking antibody [33] inhibited M ϕ –AC interaction in a dose-dependent manner (Fig. 4D). Taken together these data demonstrate an important role for TG2 cross-linking activity at the surface of human M ϕ in mediating AC removal.




Fig. 1. TG2 inhibitors reduce apoptotic cell clearance by macrophages. (A) Western blot analysis revealing both whole cell lysate (WCL) and cell surface (CS) TG2 expression in THP-1 cell-derived MØ (through stimulation with VD3, PMA or both (DS)) and primary HMDMØ. THP-1/PMA, THP-1/DS and HMDMØ but not undifferentiated THP-1 and THP-1/VD3 showed detectable TG2 expression by western blotting (left panel). Cell surface TG2 was detected specifically following cell surface protein biotinylation, prior to isolation of biotinylated proteins using Neutr-Avidin as described in the [Materials and methods](#) section. Equal loading was verified by probing with mouse anti-tubulin antibody on stripped membranes. Similarly, surface expression of TG2 in THP-1/DS was revealed upon indirect immunofluorescence staining of live (i.e. unpermeabilised) cells with mouse monoclonal anti-TG2 antibody (Cub7402) in conjugation with FITC-conjugated anti-mouse secondary antibody (right panel). Nuclei were stained with DAPI. The bar corresponds to 25 μm. (B) Dose-dependent effect of three site-directed irreversible TG2 inhibitors on MØ (THP-1/DS) interaction with AC. Inhibitors were applied to MØ for 1 h prior to and throughout the co-culture with AC. 'Interaction' is defined as the combination of those AC tethered (bound) to the surface of MØ and those internalised (phagocytosed). (C) TG2 inhibitors (including cell-impermeable R281 and its more water soluble counterpart R294) inhibited MØ (THP-1/DS) tethering of AC (i.e. where only surface binding of AC to MØ is assayed without contribution from phagocytic events) and, (D) a similar effect of TG2 inhibitors is seen in HMDMØ interacting with AC. (E) Treatment of either MØ alone or AC alone with TG2 inhibitors showed significant reduction in MØ-AC interaction following inhibitor treatment of MØ. Data shown are mean ± S.E. for $n \geq 3$ independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test ($*P < 0.05$; $***P < 0.001$).

3.5. TG2 associates with syndecan-4

We next investigated the involvement of TG2 binding partners at the human MØ cell surface. In other cells, TG2 has been shown to have a strong binding affinity for heparan sulphates (HS) of the cell surface receptor syndecan-4 that is important in the translocation of TG2 to the cell surface and extracellular matrix (ECM) [5,11]. Thus an attractive candidate partner was syndecan-4, a heparan sulphate proteoglycan (HSPG) that acts as a receptor for TG2 via its HS chains thus mediating an RGD-independent cell adhesion via a TG2-FN complex [6]. Through the use of western blotting and immunofluorescence staining (Fig. 5A)

we demonstrate a clear expression of syndecan-4 in THP-1/DS cells that also shows a strong TG2 expression. To confirm a possible interaction between cell surface TG2 and syndecan-4, we performed co-immunoprecipitation assays and demonstrate a TG2-syndecan-4 interaction in MØ cells (Fig. 5B and Supplementary Fig. 1B).

3.6. Loss of cell surface heparan sulphates or syndecan-4 reduces cell surface TG2 expression and activity resulting in reduced MØ-AC interaction

HS on HSPGs (e.g. syndecan-4) mediate TG2 binding at cell surfaces [5,11]. In order to test the importance of HS and syndecan-4 in




Fig. 2. TG2 inhibition reduces macrophage migration to AC. (A) The effect of TG2 inhibitor R281 on MØ (THP-1/DS) migration towards AC was tested using a Dunn chemotaxis chamber coupled with time-lapse imaging phase contrast microscopy over 20 h. MØ were pre-treated for 1 h with the inhibitor prior to exposure to AC in a Dunn chamber. Cell migration was tracked using ImageJ software and tracks were analysed using Chemotaxis and Migration Tool 2.0 (IBIDI), and were plotted as distance migrated (μm). The track of each cell is shown, starting at the cross hairs and finishing at a dot, with the position of the attractant at the top of each plot. Representative plots are shown. R281, a cell-impermeable TG2 inhibitor induced a dramatic reduction in MØ migration. A loss of directionality is shown in the rose diagram (insets). (B) The distance migrated and the velocity at which the cells migrate in the presence and absence of TG2 inhibitor (R281) are presented as mean \pm S.E. for $n \geq 3$ independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test (** $P < 0.01$; *** $P < 0.001$).

presenting TG2 at the human macrophage cell surface where it mediates AC clearance, we studied the effect of HS removal, syndecan-4 knockdown and blocking TG2–syndecan-4 binding on MØ–AC interaction. Loss of HS, via heparinase II treatment, resulted in loss of cell surface TG2 activity (Fig. 6A) and reduced MØ–AC interaction (Fig. 6B). Using syndecan-4 specific siRNAs, a maximal reduction in SDC4 expression (approximately 60%) was obtained (Supplementary Fig. 6A) resulting in reduced presence (Fig. 6C) and activity (Fig. 6D) of cell surface TG2 though this was only evident with the most robust knockdown of SDC4 provided by siRNA construct 2. This strongly suggests that cell surface TG2 is anchored, at least in part, to syndecan-4, the loss of which results in loss of cell surface TG2 activity. No loss of syndecan-4 expression is found in TG2 knockdown THP-1/DS (Supplementary Fig. 6B) and total TG2 expression was unaffected by loss of syndecan-4 expression.

Syndecan-4 knockdown reduces MØ–AC interaction and when syndecan-4 knockdown THP-1/DS cells were also treated with R281, no further reduction in MØ–AC interaction occurs (Fig. 6E) suggesting no additive effect and supporting the notion that the involvement of syndecan-4 or TG2 in AC clearance is functionally related. These data confirm HS as prime receptors for TG2 binding on the MØ cell surface and syndecan-4 as one HSPG important for TG2 binding.


To further strengthen our understanding of TG2–syndecan-4 binding via HS, we used the P1 peptide ($^{200}\text{NPKFLKNAGRDCSRRSS}^{216}$), which mimics the heparin binding domain within TG2 and competes for its binding to syndecan-4 [8]. Cells were treated with P1 peptide or a scrambled control P1 peptide for 30 min and here we demonstrate that the P1 peptide (but not the scrambled control peptide) reduces MØ–AC interaction (Fig. 6F) in a dose-dependent manner

(Supplementary Fig. 6C). However, upon exogenous addition of active TG2, the loss of MØ–AC interaction was found to be partially compensated (Fig. 6F), suggesting that TG-2 bound to syndecan-4 via HS is crucial in mediating MØ–AC interaction.


3.7. TG2 interacts with CD44 at the MØ cell surface: A possible TG2 mediated CD44 cross-linking

CD44, an HSPG and established receptor for hyaluronan, is important in immune cells' proliferation and differentiation, cell adhesion, migration, and inflammation [34–36]. CD44 undergoes complex alternative mRNA splicing and posttranslational modifications resulting in a family of isoforms with distinct biological functions [37]. CD44 is a known phagocytic receptor [38] that, when cross-linked by antibody, augments AC clearance [20]. We therefore investigated whether TG2 may mediate CD44 crosslinking to facilitate AC clearance.

Initially we examined CD44 expression and found it paralleled TG2 expression (Fig. 7A) in THP-1/DS, THP-1/PMA and HMDMØ. Interestingly, two major distinct molecular weight bands for CD44 were expressed. To address the possibility that the high molecular weight CD44 is a TG2 cross-linked form (cross-linked to itself or other molecules), CD44 expression in TG2 inhibitor-treated cells was examined. Inhibition of TG2 was associated with a loss in the intensity of the high molecular CD44 (~150 kDa) and an increase in the intensity of low molecular weight CD44 (~85 kDa) consistent with the notion that the high molecular weight CD44 species arises from TG2 activity (Fig. 7B). Precipitation of TG2 resulted in the co-precipitation of CD44 (Fig. 7C) suggesting a possible TG2–CD44 interaction. Importantly, in support of the small molecular CD44 species being a substrate of TG2



following prior treatment with the non-cell-permeable inhibitor R281 the presence of the high molecular weight CD44 species was barely detectable in primary human macrophages (Fig. 7D). To further confirm that CD44 is a potential substrate of macrophage cell surface TG2, THP-1/DS were incubated with the TG2 primary amine substrate biotin-cadaverine (BTC). Following cell lysis, proteins with TG2 incorporated BTC were affinity purified with Neutr-Avidin-Agarose resin beads. Western blot analysis for CD44 revealed that both high and low molecular weight bands for CD44 were present (Fig. 8A). However, treatment with the TG2 irreversible inhibitor R281 prior to BTC incorporation resulted in a significant loss in high molecular weight CD44 (Fig. 8A) confirming that CD44 is a potential substrate for cell surface TG2. Whilst R281 is an irreversible inhibitor of TG2, the inhibition is incomplete (Fig. 4B) and this provides an explanation of why there is BTC incorporation remaining even in the presence of TG2 inhibitors. The cell surface interaction of TG2 with CD44 was confirmed by immunofluorescence analysis of TG2 and CD44 which showed co-localisation of CD44 with TG2, although not all TG2 showed co-localisation with CD44 (Fig. 8B). This provides further evidence that TG2 interacts with CD44 supporting both the co-immunoprecipitation analysis and BTC incorporation studies. To study the effect of TG2-CD44 interaction on MØ ability to interact with AC, a MØ-AC interaction assay was performed following CD44



knockdown in MØ. CD44 siRNA-9 caused a significant reduction in CD44 expression in comparison to NS siRNA (Supplementary Fig. 7A), and loss of CD44 resulted in reduced MØ-AC interaction by around 40% when compared to the NS siRNA transfected cells (Fig. 8C). There was no effect on cell surface TG2 expression (Supplementary Fig. 7B). Interestingly, treating MØ with TG2 inhibitor R281 or treating CD44 siRNA-9 transfected MØ with R281 showed a further reduction in the MØ-AC interaction, suggesting that TG2 can act independently of CD44, possibly through syndecan 4.

4. Discussion

Phagocytic removal of apoptotic cells involves an array of phagocyte receptors which, directly or indirectly via soluble bridging molecules, facilitate recognition and binding of AC associated ligands ultimately leading to corpse uptake [16,17]. As evident from previous studies using TG2 deficient mice, TG2 plays a prominent role in AC engulfment by promoting phagocytic portal formation [18,19]. It is also crucially important in immune modulation to prevent inflammation and autoimmunity [18]. Here we extend those studies to characterise TG2 in AC clearance and address its location and function in human macrophages. Using a TG2-inhibitor-based approach, rather than TG2-deficient animals, we address TG2 in human cells that have developed in a TG2-replete status before specifically inhibiting TG-2 activity or expression.




Fig. 5. Macrophage cell surface TG2 associates with syndecan-4. (A) Western blot analysis (left panel) reveals the expression of syndecan-4 (detected with mouse anti-SDC4 mAb) in undifferentiated and a panel of differentiated THP-1 M0 cells. Stripped membranes were re-probed with mouse anti- α -tubulin antibody as a loading control. Similarly, syndecan 4 expression at the cell surface of THP-1/DS M0 was detected using indirect immunofluorescence (mAb to syndecan-4; goat anti-mouse FITC) and confocal imaging. (B) Interaction between TG2 and syndecan-4 in THP-1/DS M0 is revealed by co-immunoprecipitation analyses. Syndecan-4 (SDC4) was precipitated using an anti-SDC4 antibody. Precipitated material was separated by PAGE and co-precipitation of TG2 assessed by anti-TG2 western blotting (using mouse anti-TG2 mAb; anti-mouse-HRP).

Thus taking our results together with those existing, we provide a comprehensive view of TG2 function in AC clearance.

Our initial western blot studies addressed whole cell and cell surface TG2 expression in a panel of THP-1 cell-derived macrophage models and HMDM0. These cells expressed TG2 at the cell surface [39] with the exception of THP-1 parental cells and THP-1/VD3 cells where TG2 was not detectable. Given the monocyte-like (relatively immature) morphology of these cells [28], these data suggest that TG2 expression is linked to monocyte/macrophage maturity [40,41].

Building on the important previous work in mice, we assessed TG2 in human M0 through the use of irreversible site-directed TG2 inhibitors [22] including proven cell-permeable (Z-DON, Zedira) or cell-impermeable (R281) inhibitors. All the inhibitors tested strongly reduced M0-AC interaction (i.e. tethering and phagocytosis combined) and tethering (binding alone) by those M0 that expressed TG2. Importantly, similar results were noted for primary human M0. Detection of TG-2 expression at the M0 surface coupled with the ability of cell-impermeable inhibitors and a TG2-specific inactivating antibody to reduce M0-AC interaction suggests that M0 cell surface TG2 plays a prominent role in M0-AC interaction. To address the issue of inhibitor-induced conformational changes of TG2, as an explanation for reduced M0-AC interaction, the competitive TG2-substrate MDC was employed since it blocks TG2-induced protein crosslinking in the presence of Ca^{2+} without any irreversible change in TG2 conformation [32]. Again we demonstrated a significant reduction in M0-AC interaction confirming TG2 crosslinking activity as required for AC clearance by human macrophages. This conclusion is further supported by our use of siRNA to knockdown TG2 that resulted in reduced expression and cell surface activity of TG2. Taken together, with the ability of the TG2 activity-blocking antibody to reduce M0-AC interaction, these data demonstrate for the first time that TG2 on the surface of human M0 is important in the tethering and removal of apoptotic cells. Importantly we show a requirement for TG2 crosslinking activity in this function. In addition to TG2, macrophages are known to express

Factor XIIIa (another TG family members) [42,40]. To rule out the involvement of this enzyme in macrophage-AC interactions we used a TG2-specific inactivating mAb. Additionally we used the irreversible TG2 inhibitors R294 (that has an IC_{50} for Factor XIIIa of greater than 200 μM but has an IC_{50} for TG2 of 8 μM) and R281 (which also has an IC_{50} for Factor XIIIa of greater than 100 μM but an IC_{50} for TG2 of 10 μM) [24]. In addition, we also used TG2 targeted siRNA. The use of the inactivating TG2 mAb and the use of TG2 targeted siRNA will also rule out the involvement of other possible isoforms of TG that might be present.

Removal of AC in vivo is preceded by M0 migration to sites of cell death [30]. Since TG2 cell surface activity has also been reported to be important in cell migration [12,43] we investigated the ability of TG2 inhibitors to modulate M0 migration towards AC using a horizontal migration chamber. We demonstrate that inhibition of TG2 reduces both the velocity and distance migrated by M0 in response to AC and results in a complete loss of directionality. These data suggest that TG2 is involved in M0 migration. As syndecan-4 is known to be a key signalling receptor determining directional migration [44], loss of TG2 which is known to be a strong binding partner would have resulted in loss of directional migration. However, it is unclear if this effect is mediated through reduced cell adhesion or reduced detection of 'find me' signals released from apoptotic cells and this requires further study.

In light of the importance of cell surface TG2 in our studies, we addressed the mechanism by which TG2 may arrive at the M0 surface. Syndecan-4, a HSPG, has been shown to act, in non-M0, as a receptor for TG2 via its HS chains where it can mediate TG2 translocation to the cell surface and ECM [5,11]. Here we demonstrate syndecan-4 expression in all our THP-1 cell-derived models, irrespective of their TG2 expression. Through co-immunoprecipitation studies we demonstrated that syndecan-4 interacts with TG2 (where expressed), consistent with earlier studies [5,6,8,10]. Loss of syndecan-4 or cell surface HS resulted in a significant loss of cell surface TG2 expression and activity, affecting M0-AC interaction. Interestingly, whilst two different siRNA constructs for syndecan-4 resulted in reduced syndecan-4 expression, only the most robust blockade of syndecan-4 impacted on surface TG2 expression and activity, possibly suggesting that a threshold of syndecan 4 is required on the cell surface for TG2 function. Taken together with the inhibitory effect of the P1 peptide, which mimics the syndecan-4 binding domain within the TG2 molecule [8], and which can be rescued through the addition of exogenous TG2, these data support the notion that cell surface TG2, in association with HS of syndecan-4 mediates M0-AC interaction. Sequential knockdown of syndecan-4 expression and inhibition of TG2 activity together showed no further reduction in AC clearance suggesting TG2 exerts most, if not all of its cell surface effects on AC clearance through its association with syndecan-4.

Interaction of cell surface adhesion molecules either with ECM components or neighbouring cells are known to influence cell behaviour including phagocytosis. CD44, a principal surface receptor for the ECM molecule hyaluronan (a well-known cell-cell and cell-matrix interaction mediator), is known for recruiting monocytes to sites of inflammation [45] and is implicated in AC clearance [46]. Furthermore CD44, an HSPG, is a known phagocytic receptor [38] that, when cross-linked experimentally by antibody augments AC clearance by an, as yet, incompletely defined mechanism [20]. In light of these pieces of information, we hypothesised that TG2 might modulate AC clearance by mediating CD44 cross-linking to promote AC clearance. Co-immunoprecipitation studies revealed an interaction between TG2 and CD44 but this may be a direct or indirect interaction. CD44 was also detected at the M0 cell surface and was detected in TG2-expressing M0 (THP-derived or HMDM0) as two distinct molecular weight bands. CD44 exists in variant isoforms as a result of alternative splicing or variable N- and O-linked glycosylation [36,47,48]. CD44 is the most prevalent form (40 kDa) and with extensive post-translation glycosylation can increase in mass (80 kDa) [49,50]. Notably, TG2 inhibition with a cell-impermeable inhibitor resulted in reduced high




Fig. 6. TG2 associates with syndecan-4 heparan sulphate side chains and mediates macrophage–apoptotic cell interaction. Cell surface activity of TG2, and MØ–AC interaction was assessed following treatment of MØ (THP-1/DS) with heparinase II (HepII) or chondroitinase (Chon) as described in the *Methods* section. (A) TG activity is reduced following treatment with heparinase II to remove heparan sulphate chains. (B) Treatment of MØ with heparinase II also resulted in significant loss of MØ interaction with AC. (C) Western blot analysis of TG2 (whole cell TG2 or cell surface TG2 isolated following cell surface biotinylation and Neutr-Avidin isolation of cell surface components) in MØ (THP/DS) cells transfected with syndecan-4 specific siRNA or a non-specific (NS) siRNA. This reveals a loss of cell surface (but not whole cell) TG2 when syndecan-4 expression is reduced. (D) Following siRNA-mediated syndecan-4 knockdown in MØ (THP/DS) with the indicated siRNA constructs, cell surface TG2 activity was assessed and shows a loss of cell surface TG activity. (E) Syndecan-4 knockdown with siRNA (construct siRNA 2) in MØ (THP/DS) was undertaken prior to assessing MØ–AC interaction. Addition of R281 was also included (for 1 h prior to co-culture and throughout the co-culture period) to assess additive effects. (F) MØ (THP-1/DS) treated with P1 peptide for 1 h prior to co-culture and throughout the co-culture period (P1; which competes with the heparin binding domain within the TG2) but not a scrambled P1 peptide (P1s) show reduced interaction with AC, that is rescued when 200 ng purified exogenous TG2 (exoTG2) is added. Data shown are mean \pm S.E. for $n \geq 3$ independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test ($***P < 0.001$).

molecular CD44 and an increased intensity of low molecular weight CD44. Biotin cadaverine incorporation by cell surface TG2 and subsequent pulling down of labelled substrates with Neutr-Avidin and probing for CD44 on western blot showed high and low molecular weight CD44 but a loss of high molecular weight CD44 was evident upon treatment with TG2 inhibitor R281 prior to biotin-cadaverine incorporation. This confirms that in situ CD44 is a potential substrate of MØ–cell surface TG2. These data suggest that CD44 is a substrate of TG2 and can be cross-linked by the enzyme via a mechanism requiring its binding to cell surface HS. This may provide a physiological equivalent of antibody cross-linking to augment AC clearance by MØ [20]. Taken together, our data support the hypothesis that TG2 exerts its effect on AC clearance through the cell surface association with its high affinity binding partner syndecan-4 and that this may be due, at least in part, through CD44 cross-linking. However, further work is required to

assess the details of this interaction and the subsequent downstream signalling that results.

MØ–CD44 ligation mediated augmented AC intake is evident in both in vitro and in vivo [20,51] conditions. Cuff et al. demonstrated that CD44 promotes MØ recruitment to atherosclerotic lesions (sites of extensive cell death) [52], while MØ from CD44^{-/-} mice showed delayed migration into areas of inflammation [53] and a defective clearance of AC [46]. Interestingly, our MØ migration studies revealed reduced migration and directionality following TG2 inhibition. Taken together these suggest that TG2, syndecan-4 and CD44 may work together to mediate migration to and clearance of AC. Such a mechanism for TG2 involvement in cell migration is not without precedent, since TG2 binding to syndecan-4 has also been implicated in the crosslinking of cell surface S100A4 resulting in the increased motility of mammary cancer cells [12].




Fig. 7. TG2 interacts with CD44. (A) Western blot analysis of CD44 in whole cell lysates of THP-1/PMA M0, THP-1/DS M0 and HMDM0 reveals two distinct molecular weight bands for CD44. Arrowheads indicate high and low molecular weight bands for CD44. Stripped membranes were re-probed with mouse anti- β -actin antibody as a loading control. (B) M0 (THP/DS) were treated with the indicated TG2 inhibitors for 1 h prior to cell lysis and western blot analysis for CD44. Upper panel: A representative blot showing a significant loss in high molecular CD44 (~150–160 kDa) and an increase in the intensity of low molecular weight CD44 (~85–95 kDa) in comparison to untreated M0. Stripped membranes were re-probed with anti- β -actin antibody as a loading control. Lower panel shows the ratio of the high:low molecular weight bands assessed by densitometry from three independent experiments (mean \pm S.E.). Data shown were normalised to the signal from M0 alone. (C) Immunoprecipitation of TG2 from membrane lysates of THP-1/DS M0 and primary HMDM0 cells was undertaken and probed on western blot for CD44. This reveals an interaction between TG2 and CD44 proteins. (D) Upper panel: western blot analysis of CD44 from immunoprecipitates of TG2 following inhibition of TG2 with R281 in HMDM0 (representative blot); the lower panel shows the ratio of the high:low molecular weight bands assessed by densitometry from three independent experiments (mean \pm S.E.). Arrowheads indicate high and low molecular weight bands for CD44. HC indicates heavy chain and LC indicates light chain. Statistical analysis was conducted using ANOVA followed by Dunnett's post-test (* $P < 0.05$; ** $P < 0.01$, *** $P < 0.001$).

Overall, it seems likely that the binding of TG2 to cell surface heparan sulphates (e.g. on syndecan 4, CD44 and potentially other molecules), which are required for its translocation to the M0 cell surface, may provide the platform for TG2's interaction with a range of other cell surface molecules to mediate a range of TG2-mediated functions. Such functions may include those where the enzyme is brought into contact with substrates (such as CD44, S100A4 or the large latent TGF- β binding proteins) and also other high-affinity binding proteins such as fibronectin and integrins ($\beta 1$ and $\beta 3$), the latter of which are needed for cell adhesion, migration [40] and phagocytosis [19]. Indeed this may help to explain the compensatory increase in $\beta 3$ integrin expression as seen in macrophages from TG2 $^{-/-}$ animals. To date the molecular mechanism by which CD44-augmented phagocytosis occurs remains to be elucidated but it has been shown unequivocally to be independent of serum opsonins and glucocorticoid-induced Mer-tk/protein S

pathway [20]. CD44 crosslinking has been suggested to stabilise AC-M0 interactions through an ill-defined mechanism but the proposal that CD44 is a substrate for TG2 raises the possibility of a functional link between CD44 and the established role of TG2 in the development of phagocytic portals [19].

In conclusion, we demonstrate that TG2 associates with HS during its translocation to the cell surface of human macrophages. At this site, in association with syndecan-4, its crosslinking activity is central for it to exert its effect on AC removal, at least in part, by promoting the tethering of AC. However TG2 is also involved in human M0 migration to dying cells, raising the possibility that TG2 inhibitors may be used to modulate M0 migration for therapeutic gain, in those situations where M0 migration to dying cells is not beneficial. We further reveal a novel TG2-CD44 interaction and demonstrate that CD44 is a potential substrate of TG2 and that inhibition of TG2 activity reduces high




Fig. 8. CD44 acts as a substrate for TG2 in mediating apoptotic cell clearance. (A) THP-1/DS M0 was exposed, in the presence or absence of TG2 inhibitor R281, to biotin-cadaverine (BTC) as a measure of cell surface TG2 activity. Where R281 was used, M0 was pre-treated with an inhibitor for 1 h prior to the addition of BTC. Following BTC incorporation, cell lysates of THP-1/DS M0 were subject to pulldown of biotin-containing molecules by Neutr-Avidin-Agarose resin beads. The pulldowns were probed by western blotting for CD44 to reveal TG2-mediated BTC incorporation into CD44. This reveals incorporation of biotin-cadaverine into CD44 proteins in TG2 expressing cells and reduced incorporation upon treatment with non-permeable TG2 inhibitor R281. Arrowheads indicate high and low molecular weight bands for CD44. A significant loss in high molecular CD44 (~150–160 kDa) in comparison to untreated M0 is shown. (B) cell surface TG2 (red) and CD44 (green) on the M0 cell surface were stained by indirect immunofluorescence, incubating live cells with rabbit anti-TG2 and mouse anti-CD44 primary antibodies. Cells were further stained with a secondary reagent (anti-rabbit-PE; anti-mouse-FITC). TG2 co-localizes with CD44 on the M0 cell surface (MERGE/yellow). Staining is visualized by confocal microscopy. (C) CD44 and/or SDC4 knockdown with siRNA in M0 (THP/DS) was undertaken prior to assessing M0–AC interaction. Addition of R281 was also included to assess additive effects. Data shown are mean \pm S.E. For $n \geq 3$ independent replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni post-test ($***P < 0.001$).

molecular weight CD44 complexes. Such complexes may play a role in augmenting AC clearance at least in part through CD44 cross-linking. This is entirely compatible with established ability of TG2 to function with MFG-E8 and $\beta 3$ integrin to remove AC and mediate its uptake via signalling the recruitment of the CrkII–DOCK180–Rac1 complex and thus activating GTPase Rac1 [21]. Further work is now needed to assess, in detail, the importance of CD44–TG2 interactions to AC clearance and to define the nature of the TG2-mediated high molecular mass complexes that result.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.bbamcr.2014.09.020>.

Acknowledgements

We are grateful to Charlotte E. Bland (ARCHA) for expert microscopy support and Prof. Christopher D. Gregory (Edinburgh University) for provision of the Mutu B cell line. This work was funded in part by the EC FP7 ITN TRANSPATH, Grant No. 289964 and IAPP TRANSCOM,

Grant No. 251506. This work was funded in part by an Aston University International Bursary.

References

- Griffin, R. Casadio, C.M. Bergamini, Transglutaminases: nature's biological glues, *Biochem. J.* 368 (Pt 2) (2002) 377–396.
- Thomazy, L. Fesus, Differential expression of tissue transglutaminase in human cells. An immunohistochemical study, *Cell Tissue Res.* 255 (1) (1989) 215–224.
- Verderio, B. Nicholas, S. Gross, M. Griffin, Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment, and cell death, *Exp. Cell Res.* 239 (1) (1998) 119–138.
- Akimov, D. Krylov, L.F. Fleischman, A.M. Belkin, Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin, *J. Cell Biol.* 148 (4) (2000) 825–838.
- Scarpellini, R. Germack, H. Lortat-Jacob, T. Muramatsu, E. Billett, T. Johnson, et al., Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2, *J. Biol. Chem.* 284 (27) (2009) 18411–18423.
- Wang, R.J. Collighan, S.R. Gross, E.H. Danen, G. Orend, D. Telci, et al., RGD-independent cell adhesion via a tissue transglutaminase–fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 and $(\alpha 5)\beta 1$ integrin co-signaling, *J. Biol. Chem.* 285 (51) (2010) 40212–40229.
- Wang, D. Telci, M. Griffin, Importance of syndecan-4 and syndecan-2 in osteoblast cell adhesion and survival mediated by a tissue transglutaminase–fibronectin complex, *Exp. Cell Res.* 317 (3) (2011) 367–381.
- Wang, R.J. Collighan, K. Pytel, D.L. Rathbone, X. Li, M. Griffin, Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling, *J. Biol. Chem.* 287 (16) (2012) 13063–13083.
- Lorand, R.M. Graham, Transglutaminases: crosslinking enzymes with pleiotropic functions, *Nat. Rev. Mol. Cell Biol.* 4 (2) (2003) 140–156.
- Telci, Z. Wang, X. Li, E.A. Verderio, M.J. Humphries, M. Baccarini, et al., Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and $\beta 1$ integrin co-signaling, *J. Biol. Chem.* 283 (30) (2008) 20937–20947.
- Wang, M. Griffin, TG2, a novel extracellular protein with multiple functions, *Amino Acids* 42 (2–3) (2012) 939–949.
- Wang, M. Griffin, The role of TG2 in regulating S100A4-mediated mammary tumour cell migration, *PLoS One* 8 (3) (2013) e57017.
- Savill, I. Dransfield, C. Gregory, C. Haslett, A blast from the past: clearance of apoptotic cells regulates immune responses, *Nat. Rev. Immunol.* 2 (12) (2002) 965–975.
- Grimsley, K.S. Ravichandran, Cues for apoptotic cell engulfment: eat-me, don't eat-me and come-get-me signals, *Trends Cell Biol.* 13 (12) (2003) 648–656.
- C.D. Gregory, A. Devitt, The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? *Immunology* 113 (1) (2004) 1–14.
- Devitt, L.J. Marshall, The innate immune system and the clearance of apoptotic cells, *J. Leukoc. Biol.* 90 (3) (2011) 447–457.
- Hochreiter-Hufford, K.S. Ravichandran, Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion, *Cold Spring Harb. Perspect. Biol.* 5 (1) (2013) a008748.
- Szondy, Z. Sarang, P. Molnar, T. Nemeth, M. Piacentini, P.G. Mastroberardino, et al., Transglutaminase 2^{-/-} mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells, *Proc. Natl. Acad. Sci. U.S.A.* 100 (13) (2003) 7812–7817.
- Toth, E. Garabuczi, Z. Sarang, G. Vereb, G. Vamosi, D. Aeschlimann, et al., Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells, *J. Immunol.* 182 (4) (2009) 2084–2092.
- S.P. Hart, A.G. Rossi, C. Haslett, I. Dransfield, Characterization of the effects of cross-linking of macrophage CD44 associated with increased phagocytosis of apoptotic PMN, *PLoS One* 7 (3) (2012) e33142.
- K.F. Freund, K.P. Doshi, S.L. Gaul, D.A. Claremont, D.C. Remy, J.J. Baldwin, et al., Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation, *Biochemistry* 33 (33) (1994) 10109–10119.
- Griffin, A. Mongeot, R. Collighan, R.E. Saint, R.A. Jones, I.G. Coutts, et al., Synthesis of potent water-soluble tissue transglutaminase inhibitors, *Bioorg. Med. Chem. Lett.* 18 (20) (2008) 5559–5562.
- Baumgartner, N. Golenhofen, A. Weth, T. Hiiragi, R. Saint, M. Griffin, et al., Role of transglutaminase 1 in stabilisation of intercellular junctions of the vascular endothelium, *Histochem. Cell Biol.* 122 (1) (2004) 17–25.
- Badarau, R.J. Collighan, M. Griffin, Recent advances in the development of tissue transglutaminase (TG2) inhibitors, *Amino Acids* 44 (1) (2013) 119–127.
- C.D. Gregory, C. Dive, S. Henderson, C.A. Smith, G.T. Williams, J. Gordon, et al., Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis, *Nature* 349 (6310) (1991) 612–614.
- Haslett, L.A. Guthrie, M.M. Kopaniak, R.B. Johnston Jr., P.M. Henson, Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide, *Am. J. Pathol.* 119 (1) (1985) 101–110.
- Devitt, O.D. Moffatt, C. Raykundalia, J.D. Capra, D.L. Simmons, C.D. Gregory, Human CD14 mediates recognition and phagocytosis of apoptotic cells, *Nature* 392 (6675) (1998) 505–509.
- Thomas, A. Bielemeier, P.A. Lambert, R.P. Darveau, L.J. Marshall, A. Devitt, The N-terminus of CD14 acts to bind apoptotic cells and confers rapid-tethering capabilities on non-myeloid cells, *PLoS One* 8 (7) (2013) e70691.
- Torr, D.H. Gardner, L. Thomas, D.M. Goodall, A. Bielemeier, R. Willetts, et al., Apoptotic cell-derived ICAM-3 promotes both macrophage chemoattraction to and tethering of apoptotic cells, *Cell Death Differ.* 19 (4) (2012) 671–679.

- [30] A. Devitt, K.G. Parker, C.A. Ogden, C. Oldreive, M.F. Clay, L.A. Melville, et al., Persistence of apoptotic cells without autoimmune disease or inflammation in CD14^{-/-} mice, *J. Cell Biol.* 167 (6) (2004) 1161–1170.
- [31] S. Chaubey, A.J. Ridley, C.M. Wells, Using the Dunn chemotaxis chamber to analyze primary cell migration in real time, *Methods Mol. Biol.* 769 (2011) 41–51.
- [32] M. Siegel, C. Khosla, Transglutaminase 2 inhibitors and their therapeutic role in disease states, *Pharmacol. Ther.* 115 (2) (2007) 232–245.
- [33] Z. Wang, M. Perez, S. Caza, G. Melino, T.S. Johnson, K. Lindfors, et al., A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis, *Cell Death Dis.* 4 (2013) e808.
- [34] V.A. Fadok, D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, P.M. Henson, Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF- β , PGE₂, and PAF, *J. Clin. Invest.* 101 (4) (1998) 890–898.
- [35] E. Pure, C.A. Cuff, A crucial role for CD44 in inflammation, *Trends Mol. Med.* 7 (5) (2001) 213–221.
- [36] H. Ponta, L. Sherman, P.A. Herrlich, CD44: from adhesion molecules to signalling regulators, *Nat. Rev. Mol. Cell Biol.* 4 (1) (2003) 33–45.
- [37] G.R. Screaton, M.V. Bell, D.G. Jackson, F.B. Cornelis, U. Gerth, J.I. Bell, Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons, *Proc. Natl. Acad. Sci. U. S. A.* 89 (24) (1992) 12160–12164.
- [38] E. Vachon, R. Martin, J. Plumb, V. Kwok, R.W. Vandivier, M. Glogauer, et al., CD44 is a phagocytic receptor, *Blood* 107 (10) (2006) 4149–4158.
- [39] J. Hodrea, M.A. Demeny, G. Majai, Z. Sarang, I.R. Korponay-Szabo, L. Fesus, Transglutaminase 2 is expressed and active on the surface of human monocyte-derived dendritic cells and macrophages, *Immunol. Lett.* 130 (1–2) (2010) 74–81.
- [40] S.S. Akimov, A.M. Belkin, Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin, *Blood* 98 (5) (2001) 1567–1576.
- [41] S. Thomas-Ecker, A. Lindecke, W. Hatzmann, C. Kaltschmidt, K.S. Zanker, T. Dittmar, Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells, *Proc. Natl. Acad. Sci. U. S. A.* 104 (13) (2007) 5539–5544.
- [42] B. Seiving, K. Ohlsson, C. Linder, P. Stenberg, Transglutaminase differentiation during maturation of human blood monocytes to macrophages, *Eur. J. Haematol.* 46 (5) (1991) 263–271.
- [43] M.E. van Strien, J.J. Breve, S. Fratantoni, M.W. Schreurs, J.G. Bol, C.A. Jongenelen, et al., Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration? *PLoS One* 6 (9) (2011) e25037.
- [44] M.D. Bass, K.A. Roach, M.R. Morgan, Z. Mostafavi-Pour, T. Schoen, T. Muramatsu, et al., Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix, *J. Cell Biol.* 177 (3) (2007) 527–538.
- [45] V.A. Guazzone, B. Denduchis, L. Lustig, Involvement of CD44 in leukocyte recruitment to the rat testis in experimental autoimmune orchitis, *Reproduction* 129 (5) (2005) 603–609.
- [46] P. Teder, R.W. Vandivier, D. Jiang, J. Liang, L. Cohn, E. Pure, et al., Resolution of lung inflammation by CD44, *Science* 296 (5565) (2002) 155–158.
- [47] M.C. Levesque, B.F. Haynes, TNF α and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44, *Cell. Immunol.* 193 (2) (1999) 209–218.
- [48] D. Naor, R.V. Sionov, D. Ish-Shalom, CD44: structure, function, and association with the malignant process, *Adv. Cancer Res.* 71 (1997) 241–319.
- [49] C. Underhill, CD44: the hyaluronan receptor, *J. Cell Sci.* 103 (Pt 2) (1992) 293–298.
- [50] C.R. Mackay, H.J. Terpe, R. Stauder, W.L. Marston, H. Stark, U. Gunthert, Expression and modulation of CD44 variant isoforms in humans, *J. Cell Biol.* 124 (1–2) (1994) 71–82.
- [51] S.P. Hart, G.J. Dougherty, C. Haslett, I. Dransfield, CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages, *J. Immunol.* 159 (2) (1997) 919–925.
- [52] C.A. Cuff, D. Kothapalli, I. Azonobi, S. Chun, Y. Zhang, R. Belkin, et al., The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation, *J. Clin. Invest.* 108 (7) (2001) 1031–1040.
- [53] R. Stoop, I. Gal, T.T. Glant, J.D. McNeish, K. Mikecz, Trafficking of CD44-deficient murine lymphocytes under normal and inflammatory conditions, *Eur. J. Immunol.* 32 (9) (2002) 2532–2542.